Merck & Co. Inc. MRK (U.S.: NYSE)
-
- $61.87 USD
- -0.83 -1.32%
-
Volume 7,574,928
-
AFTER HOURS 7:39 PM EST 11/18/16
- $61.96 0.09 0.15%
-
AFTER HOURS Vol 121,935
- Volume 7,574,928
- 65 Day Avg Vol 10,362,484
- 1 Day Range 61.73 - 62.62
- 52 Week Range 47.97 - 65.46
- Compare to Benchmark:
- DJIA
- S&P 500
- GLOBAL DOW
- NASDAQ
- Health Care/Life Sciences
- Open 62.57
- Prior Close 62.70
- 1 Day
- MRK -1.32%
- DJIA -0.19%
- S&P 500 -0.24%
- Health Care/Life Sciences -1.03%
News Merck & Co. Inc.MRK
- Sanofi to Stop Production of Bladder-Cancer Drug
- The Wall Street Journal
- Sanofi to Stop Production of Bladder-Cancer Drug BCG
- Dow Jones Newswires
- Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities
- Press Release
- 5 big hurdles to repealing Obamacare
- MarketWatch.com
- Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
- Press Release
- Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
- Press Release
- Merck Announces Presentation of New Findings for ZEPATIER(TM) (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting(R)
- Press Release
- Dow Climbs 5.4% on the Heels of Trump’s Victory
- Barron's
- New KEYTRUDA(R) (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
- Press Release
- Drug companies spend $109 million to block vote to lower drug prices
- MarketWatch.com
- Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
- Press Release
- ( MRK ABBV ) Post Earnings Coverage as Merck Smashes Earnings Expectations
- Press Release
- Gilead Sales of Hepatitis C Drugs Harvoni and Sovaldi Slump
- The Wall Street Journal
- Speaking of Dividends: This Year, the Market's Going to the Dogs Barking Buys
- Dow Jones Newswires
- This Year, the Market’s Going to the Dogs
- Barron's
- The Morning Risk Report: Changing Cyber Risk Landscape Hard to Tackle
- WSJ Blogs
- Merck Prices EUR 1.0 Billion Debt Offering
- Press Release
- Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ID Week 2016
- Press Release
- Research Reports on Drug Makers Equities -- Pfizer, Merck, AbbVie, and Johnson & Johnson
- Press Release
- Gardasil propelled Merck to a strong third quarter — but don’t expect that to last
- MarketWatch.com
- Market Misses Upside on Merck
- The Wall Street Journal
- Merck Profit Rises on Cancer Drugs, Vaccines
- The Wall Street Journal
- Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
- The Wall Street Journal
- Stocks Fall on Mixed Earnings Reports
- Dow Jones Newswires
- Stocks Fall on Mixed Earnings Reports
- Dow Jones Newswires
- Stocks Fall on Mixed Earnings Reports
- Dow Jones Newswires
- U.S. Hot Stocks: Hot Stocks to Watch
- Dow Jones Newswires
- Stocks Lifted by Upbeat Data, Earnings -- 2nd Update
- Dow Jones Newswires
- Merck Revenue and Profit Rise on Cancer Drugs, Vaccines
- Dow Jones Newswires
- Merck Announces Third-Quarter 2016 Financial Results
- Press Release
- Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
- Dow Jones Newswires
- FDA Approves Merck's KEYTRUDA(R) (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
- Press Release
- FDA Approves Merck's ZINPLAVA(TM) (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence
- Press Release
- Merck's KEYNOTE-045 Studying KEYTRUDA(R) (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
- Press Release
- ( MRK ) Blog Coverage Merck FDA Fast Tracked Antiviral Medicine Hits Phase III Target
- Press Release
- Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint
- Press Release
- Merck Research Laboratories Facilities Designated as "Milestones in Microbiology" Sites by the American Society for Microbiology
- Press Release
- Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community
- Press Release
- Learn how to target a 20% return on First Majestic Silver, or get option-trade ideas on Alder Biopharmaceuticals, Mylan, Merck & Company Incorporated and Corrections Corporation of America or any stock you choose
- Press Release
- Merck Announces Recipients of Third Annual 1 Million 'Grant for Oncology Innovation' Award
- Press Release
Key Stock Data
?
- P/E Ratio (TTM)
- The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
- Earnings Per Share (TTM)
- A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
- Market Capitalization
- Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
- Shares Outstanding
- Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
- Public Float
- The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
- Dividend Yield
- A company's dividend expressed as a percentage of its current stock price.
Key Stock Data
-
P/E Ratio (TTM)
31.57 (11/18/16) -
EPS (TTM)
$1.96 -
Market Cap
$170.58 B -
Shares Outstanding
2.77 B -
Public Float
2.76 B -
Yield
2.97% (11/18/16) -
Latest Dividend
$0.46 (10/07/16) -
Ex-Dividend Date
09/13/16
?
- Shares Sold Short
- The total number of shares of a security that have been sold short and not yet repurchased.
- Change from Last
- Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
- Percent of Float
- Total short positions relative to the number of shares available to trade.
Short Interest (10/31/16)
-
Shares Sold Short
23.36 M -
Change from Last
-14.05% -
Percent of Float
0.85%
?
- Money Flow Uptick/Downtick Ratio
- Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.
Stock Money Flow
-
Uptick/Downtick Trade Ratio
Net Money Flow ($)
-101.48 MMoney flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
Advertisement
Competitors MRK
| Company | Change | P/E (TTM) |
|---|---|---|
GSKGlaxoSmithKline PLC ADR | -0.88% | 313.15 |
NVSNovartis AG ADR | -2.62% | 25.09 |
ABTAbbott Laboratories | -1.36% | 44.00 |
BMYBristol-Myers Squibb Co. | +0.14% | 27.82 |
JNJJohnson & Johnson | -0.35% | 20.42 |
LLYEli Lilly & Co. | -1.34% | 33.59 |
PFEPfizer Inc. | -0.79% | 31.32 |
RHHVFRoche Holding AG Part. Cert. | -0.26% | 21.47 |
SNYSanofi ADR | -2.34% | 22.48 |
TEVATeva Pharmaceutical Industries Ltd. ADR | -0.85% | 22.28 |
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Alliances and Healthcare...
- Employees 68,000Sector Pharmaceuticals
- Sales or Revenue 38.77 BIndustry Health Care/Life Sciences
- 1Y Sales Change -7.92%Fiscal Year Ends December 31 Download Reports
- Kenneth C. Frazier Chairman, President & Chief Executive Officer
- Robert M. Davis Chief Financial Officer & Executive Vice President
- Clark Golestani Chief Information Officer & Executive VP
- Roger M. Perlmutter EVP & President-Merck Research Laboratories
Research & Ratings Merck & Co. Inc.MRK
Per-Share Earnings, Actuals and Estimates
| Q4 2016 Estimate Trends | |
|---|---|
| Current: | $0.89 |
| 1 month ago: | $0.94 |
| 3 months ago: | $0.93 |
| Q1 2017 Estimate Trends | |
|---|---|
| Current: | $0.92 |
| 1 month ago: | $0.93 |
| 3 months ago: | $0.93 |
Net Income
| Sep 2016 | 5-quarter trend | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | +19.61% | | ||||||||
| Sales or Revenue | 10.54 B | | ||||||||
| Sales or Revenue Growth | +6.39% | | ||||||||
| EBITDA | - | | ||||||||
| 2015 | 5-year trend | |||||||||
| Net Income Growth | -62.73% | | ||||||||
| Sales or Revenue | 38.77 B | | ||||||||
| Sales or Revenue Growth | -7.92% | | ||||||||
| EBITDA | +13.78 B | |